Percheron Therapeutics Limited has released a press release.
Antisense Therapeutics to enter clincial development in DMD
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- ATL1102 for MS Phase IIb IND submitted to the FDA
- Positive effects with ATL1102 on MS Black Hole lesions
- ATL1103 Update
- ATL1102 for MS Phase IIb Investigational New Drug Submission
- Market and Technology Update
Later from Percheron Therapeutics
- ATL1102 for Multiple Sclerosis Phase IIb trial Update
- ATL1102 Black Hole MS data to be presented at MS Conference
- ATL1102 for MS and DMD Update
- ATL1103/atesidorsen Early Access Program Agreement
- ATL1103/atesidorsen Early Access Program - Update
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics